The third in a series of bellwether trials involving Risperdal and gynecomastia is scheduled to commence today in Pennsylvania’s Philadelphia Court of Common Pleas. The trial, like two others that concluded earlier this year, is intended to test the strength of plaintiffs’ allegations in similar Risperdal lawsuits.

Risperdal is an atypical antipsychotic medication approved to treat schizophrenia and bipolar disorder in adults and adolescents, as well as irritability symptoms related to autism. While the medication was launched on the market in the early 1990s, Risperdal was not approved for any pediatric indications until 2006.

Split Decision in First Two Risperdal Gynecomastia Trials

The mass tort litigation underway in Pennsylvania currently houses more than 1,300 Risperdal cases, all of which were filed on behalf of plaintiffs who allegedly experienced excessive male breast growth and other complications related to its use. Specifically, the Risperdal gynecomastia plaintiffs accuse Johnson & Johnson and its Janssen Pharmaceuticals unit of concealing data that indicated the drug could increase the body’s production of prolactin, a hormone that plays a role in female breast development and lactation. In men and boys, higher-than-normal prolactin levels have been tied to excessive growth of breast tissue.

Risperdal lawsuits involving excessive male breast development seek monetary damages for plaintiffs’ medical bills, including the cost of surgical procedures required to remove extra breast tissue, as well as the emotional distress caused by this embarrassing condition. In some cases, plaintiffs are alleged to have developed size 46 DD breasts as a result of treatment with Risperdal. Many of the cases involving gynecomastia were filed on behalf of patients who were treated with the drug as children, long before it was approved for pediatric uses in 2006. They accuse Johnson & Johnson and Janssen of illegally promoting the use of Risperdal in children, even thought the FDA had yet to approve any pediatric indications.

According to court records, the Pennsylvania litigation concluded its first two bellwether trials involving Risperdal and gynecomastia earlier this year. The first trial ended on February 24th, with the jury awarding $2.5 million to an autistic man who experienced excessive breast growth after taking Risperdal as a child. The second trial concluded nearly a month later, with the jury finding that Johnson & Johnson and Janssen’s warnings about male breast growth were inadequate. However, the plaintiff was not awarded any monetary damages because the panel concluded that he had not proven that Risperdal caused his condition.

Considering Your Own Risperdal Lawsuit? Consult an Attorney Today.

If you or a loved one developed gynecomastia while using Risperdal, and you would like to learn more about filing your own lawsuit, please contact Bernstein Liebhard LLP today. Our attorneys are already representing a number of Risperdal gynecomastia plaintiffs, and they are available to evaluate your claim for free. Simply call 1-877-779-1414 to learn more today.

Published May 27, 2015 by